Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340119 · ClinicalTrials.gov registry record
Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 871
- Enrollment target
NCT00340119: Completed study, sponsored by National Cancer Institute (NCI).
NCT00340119 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 871 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340119 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 871 participants
- Enrollment target
Study Summary
This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patients on dialysis is extraordinarily high, accounting for about 50 percent of deaths. Blood levels of inflammatory markers are elevated in these patients, strongly predicting illness and death from CVD. The discovery of gene variants related to the inflammatory process in atherosclerotic CVD may lead to better medical treatments and improved survival in patients with end-stage kidney disease. Participants of John's Hopkins University's CHOICE (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease) program are included in this study. Blood samples previously collected from these patients will be analyzed in the laboratory for genes that might be associated with the inflammatory process and atherogenesis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 871 participants |
| Start Date | 2005-03-21 |
| Est. Completion | 2012-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00340119
The ClinicalTrials.gov registry entry for NCT00340119 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 871 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00340119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00340119 about?
NCT00340119 is a clinical study titled "Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis". This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patie...
What is the current status of trial NCT00340119?
This trial is currently completed. The enrollment target is 871 participants. The study started on 2005-03-21. Estimated completion is 2012-03-01.
Who is sponsoring clinical trial NCT00340119?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.